Idiopathic membranous nephropathy and nephrotic syndrome: Outcome in the era of evidence-based therapy

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 235-242

  McQuarrie, Emily P ^a   Stirling, Catherine M ^b   Geddes, Colin C ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

death; glomerulonephritis; proteinuria; remission; RRT

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PREDNISOLONE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; COMPLETE REMISSION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEMALE; HIRSUTISM; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MORTALITY; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PARTIAL REMISSION; PRIORITY JOURNAL; RELAPSE; REMISSION; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RISK REDUCTION; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CREATININE; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; REMISSION INDUCTION; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856631149     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr220     Document Type: Article

References (37)

1. Hanko JB, Mullan RN, O'Rourke DM et al. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant 2009; 24: 3050-3054
2. McQuarrie EP, Mackinnon B, Stewart GA et al. Membranous nephr-opathy remains the commonest primary cause of nephrotic syndrome in a northern European Caucasian population. Nephrol Dial Transplant 2010; 25: 1009-1010
3. Haas M, Meehan SM, Karrison TG et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 30: 621-631 (Pubitemid 27465355)
4. Braden GL, Mulhern JG, O'Shea MH et al. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000; 35: 878-883 (Pubitemid 30238200)
5. Polanco N, Gutierrez E, Covarsi A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704
6. Hladunewich MA, Troyanov S, Calafati J et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 2009; 4: 1417-1422
7. Marx BE, Marx M. Prediction in idiopathic membranous nephrop-athy. Kidney Int 1999; 56: 666-673
8. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-89 (Pubitemid 23188821)
9. Hogan SL, Muller KE, Jennette JC et al. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995; 25: 862-875
10. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604
11. Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-450 (Pubitemid 28122870)
12. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59: 1484-1490 (Pubitemid 32281239)
13. Troyanov S, Wall CA, Miller JA et al. Idiopathic membranous nephr-opathy: definition and relevance of a partial remission. Kidney Int 2004; 66: 1199-1205 (Pubitemid 39121029)
14. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis 2005; 46: 1012-1029 (Pubitemid 41690227)
15. Cattran DC, Pei Y, Greenwood CM et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51: 901-907 (Pubitemid 27157980)
16. Ruggenenti P, Mosconi L, Vendramin G et al. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis 2000; 35: 381-391
17. Praga M, Borstein B, Andres A et al. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 1991; 17: 330-338
18. Waldman M, Austin HA, III. Controversies in the treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 2009; 5: 469-479
19. Ponticelli C, Zucchelli P, Passerini P et al. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idio-pathic Membranous Nephropathy Treatment Study Group. N Engl J Med 1992; 327: 599-603
20. Jha V, Ganguli A, Saha TK et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18: 1899-1904 (Pubitemid 46870326)
21. Eriguchi M, Oka H, Mizobuchi T et al. Long-term outcomes of idi-opathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant 2009; 24: 3082-3088
22. Fervenza FC. Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer? Clin J Am Soc Nephrol 2009; 4: 1017-1019
23. Alexopoulos E, Papagianni A, Tsamelashvili M et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006; 21: 3127-3132 (Pubitemid 44567084)
24. Goumenos DS, Katopodis KP, Passadakis P et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am J Nephrol 2007; 27: 226-231 (Pubitemid 47164670)
25. Austin HA III, Illei GG, Braun MJ et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20: 901-911
26. Cattran DC, Alexopoulos E, Heering P et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007; 72: 1429-1447 (Pubitemid 350197945)
27. Branten AJ, du Buf-Vereijken PW, Klasen IS et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16: 169-174 (Pubitemid 43073169)
28. Ruggenenti P, Cravedi P, Sghirlanzoni MC et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008; 3: 1652-1659
29. Fervenza FC, Cosio FG, Erickson SB et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73: 117-125 (Pubitemid 350273646)
30. Segarra A, Praga M, Ramos N et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4: 1083-1088
31. Bomback AS, Derebail VK, McGregor JG et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4: 734-744
32. Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
33. Glassock RJ. The pathogenesis of idiopathic membranous nephrop-athy: a 50-year odyssey. Am J Kidney Dis 2010; 56: 157-167
34. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007; 18: 2221-2225 (Pubitemid 47203835)
35. Ordonez JD, Hiatt RA, Killebrew EJ et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44: 638-642 (Pubitemid 23265235)
36. Bjorneklett R, Vikse BE, Svarstad E et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007; 50: 396-403 (Pubitemid 47285451)
37. General Register Office for Scotland. Death Rates, by Sex and Age, Scotland 1946 to 2001. UK: GRO, 2002